NCT02379741 - ADC-1013 First-in-Human Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 8, 2017

Study Completion Date

March 8, 2017

Conditions

NeoplasmsSolid Tumors

Interventions

BIOLOGICAL

ADC-1013

Agonistic human monoclonal IgG1 anti-CD40 antibody

Trial Locations (5)

Center for Cancer Research, Department of Oncology, Herlev Hospital, Herlev

Kliniska prövningsenheten (KPE), Karolinska University Hospital, Solna

Department of Oncology, Uppsala University Hospital, Uppsala

Department of Oncology, Queen Elisabeth Hospital, Edgbaston

The Clatterbridge Cancer Centre, Bebington